Stryker (NYSE:SYK) Price Target Raised to $443.00

Stryker (NYSE:SYK) had its price objective increased by Barclays from $418.00 to $443.00 in a research note published on Monday,Benzinga reports. Barclays currently has an overweight rating on the medical technology company’s stock.

SYK has been the subject of several other reports. The Goldman Sachs Group increased their price target on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. Stifel Nicolaus raised their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, UBS Group raised their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $420.68.

Stryker Stock Performance

Shares of Stryker stock opened at $385.49 on Monday. Stryker has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a market capitalization of $146.96 billion, a PE ratio of 49.68, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. The stock’s fifty day moving average is $377.27 and its two-hundred day moving average is $366.01. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business posted $3.46 EPS. As a group, analysts expect that Stryker will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently bought and sold shares of the business. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the 4th quarter worth approximately $25,000. Dunhill Financial LLC grew its position in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Rakuten Securities Inc. raised its holdings in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker during the 4th quarter worth approximately $30,000. Finally, BankPlus Trust Department acquired a new stake in shares of Stryker in the 4th quarter valued at $33,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.